Alagebrium Chloride
Alagebrium Chloride, identified as ALT711, emerged as a pioneering pharmaceutical candidate developed by Alteon, Inc. It marked the first clinical attempt to address the crosslinks formed by advanced glycation endproducts (AGEs), a key factor in the aging process. By targeting and disrupting these crosslinks, Alagebrium aims to counteract the stiffening of blood vessel walls, a condition linked to hypertension, cardiovascular disorders, and various age-related degenerative issues caused by protein crosslinking. Clinical studies have demonstrated its efficacy in lowering systolic blood pressure and offering therapeutic advantages for individuals with diastolic dysfunction.
Product Specifications
CAS Number
341028-37-3
Purity
>98%
Smiles
[Cl-].S1C ([H]) =[N+] (C ([H]) ([H]) C (C2C ([H]) =C ([H]) C ([H]) =C ([H]) C=2[H]) =O) C (C ([H]) ([H]) [H]) =C1C ([H]) ([H]) [H]
Molecular Formula
C13H14CLNOS
Molecular Weight
267.7744
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Mouse UDP-glucuronosyltransferase 1-6 (Ugt1a6)
Recombinant Mouse UDP-glucuronosyltransferase 1-6 (Ugt1a6)
Recombinant Mouse UDP-glucuronosyltransferase 1-6 (Ugt1a6)
Lentiviral human TMEM86A shRNA (UAS) - Lentiviral human TMEM86A shRNA (UAS) (100)
